1. Home
  2. |Professionals
  3. |Julia Carbonetti

Julia Carbonetti

Counsel
Counsel
amNhcmJvbmV0dGlAY3Jvd2VsbC5jb20=
VCard
VCard

Areas of Focus

Overview

Julia Carbonetti is a counsel in the firm’s Washington, D.C. office, where she practices in the Mass Torts, Product, and Consumer Litigation Group.

Julia represents clients in complex tort and product liability matters, with a particular focus on the transportation industry. She handles all aspects of litigation, including dispositive motions, mediations, and/or arbitrations. She also has experience defending clients in breach of warranty and negligence cases.

Julia served as a law clerk to the Honorable Joseph M. Getty, Court of Appeals of Maryland, and as a judicial law clerk to the Honorable Fred S. Hecker, Circuit Court for Carroll County, Maryland. She was the Notes & Comments Editor of the Journal of Business and Technology while in law school.

Career & Education

|

    • University of Maryland, College Park, B.A., 2013
    • University of Maryland School of Law, J.D., cum laude, 2016
    • University of Maryland, College Park, B.A., 2013
    • University of Maryland School of Law, J.D., cum laude, 2016

    • Maryland
    • District of Columbia
    • U.S. District Court for the District of Maryland
    • U.S. District Court for the District of Columbia
    • Maryland
    • District of Columbia
    • U.S. District Court for the District of Maryland
    • U.S. District Court for the District of Columbia

Julia's Insights

Client Alert | 4 min read | 10.30.24

Trends in Recent FDA Warning Letters for Cosmetic and Cosmetic-Adjacent Products

The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) is the most significant expansion of FDA’s authority to regulate cosmetics in nearly 85 years.  FDA is now enforcing MoCRA’s product listing and facility registration requirements (as of July 1, 2024) along with MoCRA’s adverse event reporting, safety substantiation, recall authority, and records access requirements.  But how is FDA actually effectuating its new enforcement powers regarding cosmetics?  Below we explore two significant emerging trends that shed light on this question.  These trends reveal that at present, FDA is most focused on regulating products that exist at the nexus of the definition of “drugs” and “cosmetic products.”  In other words, FDA continues to focus on companies and products already on its radar as part of its authority over drugs....

View All Insights

Insights

Client Alert | 4 min read | 10.30.24

Trends in Recent FDA Warning Letters for Cosmetic and Cosmetic-Adjacent Products

Client Alert | 3 min read | 10.29.24

The Ink is Dry: FDA Issues Final Guidance for Tattoo Industry

Client Alert | 1 min read | 08.06.24

Cosmetics Direct Gets Two Portal “Fillers” – Discontinuation and Relisting Features Added

Client Alert | 2 min read | 06.26.24

FDA Unveils Its “First Look” Into How It Will Enforce MoCRA
|

View All Insights

Practices

Industries

Julia's Insights

Client Alert | 4 min read | 10.30.24

Trends in Recent FDA Warning Letters for Cosmetic and Cosmetic-Adjacent Products

The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) is the most significant expansion of FDA’s authority to regulate cosmetics in nearly 85 years.  FDA is now enforcing MoCRA’s product listing and facility registration requirements (as of July 1, 2024) along with MoCRA’s adverse event reporting, safety substantiation, recall authority, and records access requirements.  But how is FDA actually effectuating its new enforcement powers regarding cosmetics?  Below we explore two significant emerging trends that shed light on this question.  These trends reveal that at present, FDA is most focused on regulating products that exist at the nexus of the definition of “drugs” and “cosmetic products.”  In other words, FDA continues to focus on companies and products already on its radar as part of its authority over drugs....

View All Insights